4.80
+0.17(+3.67%)
Currency In USD
Address
1445A South 50th Street
Richmond, CA 94804
United States of America
Phone
510 806 1445
Website
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
62
First IPO Date
September 26, 2024
| Name | Title | Pay | Year Born |
| Dr. Kristen Fortney Ph.D. | Co-Founder, Chief Executive Officer, President, Treasurer, Secretary & Director | 744,392 | 1984 |
| Mr. Eric Morgen M.D. | Co-Founder, Chief Operating Officer & Director | 632,837 | 1983 |
| Dr. Paul D. Rubin M.D. | Chief Medical Officer & Executive Vice President of Research | 673,988 | 1954 |
| Dr. Carrie-Lynn Langlais Furr | Senior Vice President of Regulatory Affairs | 0 | N/A |
| Mr. BJ Sullivan Ph.D. | Chief Strategy Officer | 0 | N/A |
| Ms. Julie Gammelgard | Senior Vice President of People | 0 | N/A |
| Dr. Peng Leong M.B.A., Ph.D. | Chief Business Officer & Therapeutic Area Head of Brain Aging | 0 | N/A |
| Mr. Justin Rebo | Senior Vice President of Translational Aging Biology | 0 | N/A |
| Dr. Dov A. Goldstein M.B.A., M.D. | Chief Financial Officer | 0 | 1967 |
| Mr. Rusty Montgomery Ph.D. | Senior Vice President of Research | 0 | N/A |
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.